little cover. and different quarter Thanks, good go fast. approach Joe, a to Good to this a try quarter. lot I'll a year,
down I'll and businesses the growth we FX then in segment about Slide that changes about changes P&L walk some the business with I'm rates, of impact start X, discontinued QX level divested quarter and and XXXX. organic the of top Quick summary for full-year when businesses. for both the for a observations talk provide revenue XXXX. guidance our to of major the in impact the the the prior-year impact acquired and units to going turning before by excluding year the and periods means full reminder, of in
we Okay, and channel year held Slide the to QX quarter, X. took an the that QX reduce of organic Recall we wholesalers XXXX. inventories 'XX posted by In steps that at of estimated X% $XX revenue our versus had revenue effect that reducing last growth million.
a that's quarter. tailwind So, us this for
our Excluding lot revenue lot a but segments. the level plus of impact each still posted organic good parts, of There of the stuff inventory moving a were top contraction, we of within growth X%. of
and the erosion growth. in Let's XX% revenue with of the organically of the up contributor exclusivity generic some XX%. performance and quarter organic also continued of UCERIS XIFAXAN, RELISTOR the quarter, continued start up was with lost Salix offset XX% the contributed We largest from as growth on APRISO that growth. PLENVU it up in strong for combined
year, the While for of million revenue TRxs not up organic versus organic XXXX, a TRULANCE growth, sales factor up Salix LOEs. versus despite the QX 'XX, totaled in growth posting quarter and full XX% XX% great in a $XX were from wrap Salix quarter a year to strong
on B&L and revenue X% Consumer plus lens back was in in of organically contact brands and renu Surgical solution X% on in the by Multi-Purpose. the led organically plus for our quarter X% enVista LUMIFY Global Global organically the global eye Biotrue International strength the segment in strength was up in IOLs. the U.S. consumables quarter and
silicone in lenses organically on was in lenses, the and hydrogel ONEday strength Daily Japan X% in ULTRA monthly lenses. Global AQUALOX plus Vision our Biotrue Care SiHy quarter
brand organically the business to versus while VYZULTA PROLENSA essentially of Global decline offset declined QX family Ophtho generic of by pharma X% and 'XX were due international more than Rx was flat erosion. as of growth LOTEMAX Our the
Biotrue lenses diverse Japan. International revenue AQUALOX of contributions durable SiHy lenses, posted on Consumer mid-single-digit over the globally, organically, time. this consistent our year, with LUMIFY growth our that organically, ONEday grew the by Vision lenses the All year, strength and B&L monthly segment X% organically X% eye led and Global business in belief International the U.S. from five vitamins ULTRA deliver growth units Global followed can our for For B&L up in up Daily full our X% of our by Care with and organic
and X% brands was up up of in portfolio strength Canada. Unlike on Russia, the and Rx Egypt Our business overcame in quarter, of VYZULTA, organically growth international our year, the LOE Ophtho international ophthalmic PROLENSA was full X% organically. from a Global the for pharma drag LOTEMAX.
decline X% significant XX growth. XX%, Ortho 'XX was entire to products contributor up segment platform in versus the The QX overcame our as dermatology. for in business, solidly in is Dermatologics companywide the growth which the the THERMAGE of medical declined Solta, organically in global now In business a spectacular the Top was aesthetics and Solta nearly XX% company 'XX
JUBLIA, XXXX. strong full LOEs offset much quarterly mainly same and in more growth for grew The promoted organically a for Ortho the cream. medical big in It's pretty by Global derm decline of than medical the year, role Solta balance XX% medical of plus played QX the segment versus for derm, the all including story the Zovirax from the DUOBRII, decline ELIDEL in Derm year, BRYHALI, SILIQ products dermatology. in and
versus For our million the was growth full drag LOEs, minus year, by medical business a impacted derm $XXX XXXX. most
revenue the JUBLIA side, XXXX Top 'XX. contributors in the of one growth On companywide to plus versus was XX
to and growth moderate expected business SILIQ LOEs in of of the growth basis phase, BRYHAL, JUBLIA, return in brands that's form in with As the derm and this core for in our XXXX. together DUOBRII, an our this portfolio impact the segment, medical
branded providing which our the the generic drag organically our authorized Finally, LOEs on business organically in products with segment, lost mainly Diversified that APRISO, a the were the and quarter business, declined ELIDEL of grew versions $XX exclusivity, growth. as X% UCERIS, of the X% quarter LOTEMAX neuro million generics bulk in that
For Diversified selling revenue our volume. organically, realized from LOE our business. growth declined some drag in the generics improved as and prices neuro X% year from for X% Total X% the the grew offset X% with $XXX coming of of full organically a company growth net year, increased XX% million business
Slide X, to the summary for Flip the quarter. P&L
XX Our quarter. was with in 'XX points mainly but QX basis Project activities. favorable to was XXXX, XX.X%, big versus margin gross of with higher associated prior-year gross growth the from the inventory to impacted versus margin of our XXXX down the our XIFAXAN, year, in CORE particularly Note a mix XX.X%, by full about also improvements that write-offs driver, relative basis due QX for the XX quarter points
Our year final margin was for XX%. for full gross the guidance roughly
a Selling the launches and to to costs and unfavorable basis particularly advertising by international due expenses on versus in product and launches, in and constant-currency TRULANCE Russia. X% to Canada new QX higher Vision are in of XXXX the pharma quarter Care up were support of -- in addition Salix for the A&P portfolio
continue development to on to quarter were QX operating as expenses higher unfavorable systems. G&A ongoing X% business initiatives to basis a increased of the cost our Adjusted IT costs improve in we compared XXXX global due and work to constant-currency of
of first average the is between above point million rate, QX in XXXX, $XXX on and QX quarters XXXX. G&A over run adjusted quarterly rate the G&A to adjusted what out the three I saw be The want go-forward million run rate $XXX to that run in likely expect we I XXXX. in would is of average the
just read the in into down It's on both in how X% that. a the of constant-currency was I would basis. periods. timing R&D fell or expenses much not quarter favorable by
timing of XX% full just up our the $XXX of below constant-currency slightly R&D final on basis XXXX for was expenses million, Again, For fell. $XXX how year, a the to R&D guidance million.
to get guidance, we R&D to intend activities. I As you'll more to XXXX see capital when commit
Adjusted year, quarter the $X.XXX a below to a end EBITDA guidance on constant-currency was million, full range just top in basis, final EBITDA and enabled which post from for the up quarter plus our year-ago XXXX us a adjusted of XXXX. the for X% X% basis the of on quarter was from constant-currency billion that $XXX solid
Turning to Slide X.
back billion guidance, did of adjusted to midpoint EBITDA. look revenue a and was how taking of original of which XXXX we $X.XXX worth relative our the XXXX it's think I $X.X at in billion
The with revenue million, million, plus above base function in $XX Our reduced million, FX offsetting midpoint assets business of a acquisition a was from original $XXX favorable guidance of rates guys, the $XXX good things. was result TRULANCE actual revenue LOE XXXX changes the $XX million. four by $XX revenue added some favorable our and was of million by
and better of R&D million SG&A in points our basis The our better gross lift. LOE had EBITDA a revenue FX added million the coming adjusted factor million our initially the profit, performance no TRULANCE at than no profit, of roughly were of added was original $XXX investment was forecast, spending of $XX accounted above million biggest Adjusted in bit impact, the for impact, original in the single better EBITDA had improved $XXX margin both while view. midpoint XXX $XX base above has guidance. which
driving results came good year is the out, assets, of had of improved chain, we LOE year. our from performance and improve as to in our share played good improve efficiency our better relentless efforts activities units Project from Point to our but the story that, lion's to CORE our the businesses, gross with supply some nets, base commercial from the the in a fortune
flow to cash X, Turn summary. Slide the
at of our Our end key net API XXXX in billion, expected cash of and increased range provided operating low uninterrupted inventories products came $X.XXX certain by supply. to activities we the ensure in as
hand roughly year U.S. other and related was prepayment Note end, an Net we cash billion working on not yet notes the those and December $X.X fees, completed the as our of totaling we of that Litigation, offering $X.XXX amounts billion proceeds year $X.XX those at that's had applied of $XXX of at to payment in unsecured Securities and end $X.XX the billion. million. late of debt of billion had cash
the the the Similarly those of timing on of net balance on debt proceeds. use $X.X inflated billion end at cash sheet to due Slide debt X, are and our raise the and year
to overhanging in progress ratios, Securities and I settle the at $XX.X think uncertainty. forma our those improving the the reducing quantum our to net this. of a Settling of absolutely year but it the case, end debt us have our right significant like our it billion. been U.S. deployment set debt was of would do for leverage back Pro funds, thing and roughly quantify
the began systematically to our continue million process of thing intend Quick the calling to principal another sheet. aside, $XXX bonds. on balance We just down. One of we week, last amount last debt grind
for other the of and the case, expenses in settlement The billion accrual P&L. related is other was investigations. legacy $X.XX and total stock GAAP litigation cases, in and included During quarter, and for drop we our income accrued the ongoing U.S.
the from income. For doubt, adjusted EBITDA this the adjusted of avoidance we and expense exclude computation of net
onto the money guidance showing Finally with for me, slides Slide for and XXXX. our starting XX,
to a to Our revenue is plus that guidance of plus rates. billion growth range X% represents of and XXXX $X.XX at X% for range FX a billion of $X.XX current
rates. of a X% those a slide other range to billion growth about at adjusted $X.XX think minus how to is this elements Our representing about guidance want talking $X.X billion, current growth of guidance FX XXXX. profit our of EBITDA range X% of on the revenue plus rates and to cover to I for before
XXXX billion and plan, resources were it ahead X% $X.X In to approximately $X.X and LUMIFY, support XXXX. we to $XXX but OpEx products phases, than SG&A units, advertising look in selling, and to DUOBRII, expenses allocated million across business XXXX launch SiHy may XXXX in and The lenses, we're Adjusted we also as rationalized XXXX. and billion roughly higher increase is products including we be or promotional to our launch some for Daily several units THERMAGE. incremental guiding
and that a XXXX build continuing are organization adjusted infrastructure we increasing XXXX. G&A, cost, out G&A our and IT in our at global comes versus In to
and forward We're move million be of for from to that to the XXXX XXXX, XXXX, we roughly $XXX of able growth roughly we SG&A guiding XXXX. $XX should revenue into million As in up below hold growth. R&D
totaled you investment $XXX million. to in go If XXXX, back our R&D
core Optho Surgical few underinvested years, some we've volume that's where to increased the over investment R&D our years an the infrastructure organization commitments while and businesses. reducing the last B&L a increasing in intensity sustain each GI, product of up areas support of been to includes to That Over other number we had and Rx. and specifically areas, built of
earnings reduces growth, organic increase long-term prospects right the growth. a and While R&D deliver near-term our to enhance earnings our thing it's in to do to X%
settlement For interest of action. Securities to from the billion down billion, expense, of $X.X class billion, we're guiding of the U.S. the to addition $X.XX $X.XX despite fund debt
Our was tax rate adjusted on X.X% earnings in XXXX.
rate in towards of about that the expenditures same, XXXX expect million. we're the bottom of roughly guiding X% capital be in page, roughly note that We to to the XXXX, $XXX
lens the connection to with might roughly daily year be in CapEX determined I've in and In mainly steady million in under hydrogel of to past, state time, uptick over we've number the and and necessitate investment, the supply said IT beyond. particularly due that per in that global million of chain investment $XXX was build-out our that our Over our XXXX our investments the last XXXX $XXX initiative systems. years, increased silicone
XXXX will requirements million $XXX a XXXX CapEX current in our state, XXXX, XXXX Contingent view closer out, of and recently year. and roughly milestones $XX are that The $XXX in consideration and NOVXX. in we're again in XIPERE to after It's few years steady related investment guiding see million milestone million the per totaled rights and roughly maybe we likely decrease in was to license sales a of forecast acquired to CapEX on $XXX to payments million to RELISTOR agreements XXXX. related and increase
costs, guiding represents of settlement of to systems restructuring some these Finally, cases this investigations. restructuring estimate and XXXX, we're that I'd and point out and XXXX, item legal in $XX other, In $XX items our million. totaled million. integration
the actual from to results XXXX XX, guidance. our Slide bridge XXXX to Turning
focus on LOE the First, impact.
million is from the are good news a The $XXX impact the that putting close to drag are forecasting LOE basket finally of of assets in We the we growth of XXXX. $XXX large bucket us. XXXX In 'XX of 'XX, million. was 'XX it the it versus $XXX was LOEs was 'XX, $XXX versus behind million. drag growth 'XX, million. In versus In here
by the be the million to That's us the is any LOE more will XXXX, in will good 'XX drag. drag into future basket to of did manageable. add be We LOEs reduced. years, LOE impact to than growth looking from substantially new the expect not while realizing $XXX And expect $X.X the drag last the three to our revenues million. moderate period versus XXXX based XXXX. of XXXX, And assets the in LOE $XXX we and the decline basket was XXXX In we of out Over amount that quite on over LOE revenue to part. on trammeled billion here 'XX,
in call on plus out -- called $XXX base of by performance few million few worth that last me, I noting. our $XXX a million others things The negative is excuse a a and ways impacted
First, in nets XXXX XXXX of to to improvements the that the a growth. especially in non-recurrent portion headwind saw there and in QX that is gross are we
in is expected trajectory downward through there to of in from trajectory XXXX performer strong forewarned, the a Glumetza. been and future Next, it in the had quarters. the three the of almost -- dropped now quarters of as is we QX Glumetza half trend first before
Next and not of terrific ELIDEL. called authorized one had versions the UCERIS from generics I our in business in major out for generic performance with had we contributions XXXX and previously you,
fleeting. generic products significant that Think our see will we One of guidance lose coronavirus includes launched, for of in of our more other the meaningful It's have color, brands with China, the Asia-Pac could exclusivity. tail revenue it's have but of AGs As but an situation. declines the our associated bit region, performance as AGs a the base especially of on headwind us estimate versions been these good, XXXX. stretching in better,
includes impact. Obviously estimate $XX this revenue guidance That's an as XXXX. we'll million see this our roughly guidance plays EBITDA coronavirus a out over adjusted Our impacted well. and how
FX part are range implied rates. reason the by only growth to in items revenue guidance is of of the in X% these So, XXXX X% the at why current
to Turning self-explanatory. in LOE page, are bottom bridge EBITDA impacts the the of R&D at currency the the
that rate. SG&A these Within adjusted expectations absorbing coronavirus revenue our of implied or drivers well. are guidance adjusted by growth growth roughly on performance, our the of impacts below All items EBITDA the the together rates the our we're and ranges million $XXX increase in base X% impact as being revenue EBITDA our
you, Back That's me. it Joe. for to
